Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHELLY SENDERS

Allopathic & Osteopathic Physicians Pediatrics

NPI
1629030242
CMS profile
72774
Location
SOUTH EUCLID, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,200.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $3,200.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHELLY SENDERS

NPI 1629030242 · CMS profile ID 72774

Allopathic & Osteopathic Physicians / Pediatrics

SOUTH EUCLID, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629030242?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629030242?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629030242?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SHELLY SENDERS, NPI 1629030242, CMS profile ID 72774, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1629030242?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $3,200.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $3,200.0012/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673847431 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,200.00 1
PY2021 $20.00 1
PY2024 $19.72 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $54,019.97 12
PY2025 Principal investigator $1,902,218.36 170
PY2024 Recipient $275,103.88 9
PY2024 Principal investigator $1,504,720.66 124
PY2023 Recipient $102,576.00 31
PY2023 Principal investigator $2,132,839.28 106
PY2022 Recipient $295,641.25 8
PY2022 Principal investigator $2,774,710.46 131
PY2021 Recipient $6,400.00 2
PY2021 Principal investigator $3,331,898.39 191
PY2020 Recipient $940.00 1
PY2020 Principal investigator $1,688,992.60 356
PY2019 Principal investigator $803,780.84 320

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

137 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $175.73 12/31/2023 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 991140967
Principal investigator 1 Merck Sharp & Dohme LLC $32,697.11 12/31/2023 Non-covered Recipient Entity
Senders Pediatrics
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 1042492805
Principal investigator 1 Merck Sharp & Dohme LLC $347.16 12/31/2023 Non-covered Recipient Entity
Senders Pediatrics
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus HPV L1 Virus-Like Particle VLP Vaccine, administered in Preadolescents and Adolescents 9 to 14 year olds with a Comparison to Young Women 16 to 26 year olds No dispute reported 06/30/2026 1042565877
Principal investigator 1 PFIZER INC. $8,290.88 12/27/2023 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046364863
Principal investigator 1 PFIZER INC. $9,169.92 12/27/2023 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046368034
Principal investigator 1 PFIZER INC. $19,396.79 12/27/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 1046441251
Principal investigator 1 SANOFI PASTEUR INC. $37,924.00 12/22/2023 Non-covered Recipient Entity
Dr Shelly David Senders Md Inc
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 1035903505
Principal investigator 1 PFIZER INC. $7,390.50 12/21/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046364657
Principal investigator 1 ModernaTX, Inc. $70,902.00 12/20/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042219155
Principal investigator 1 Merck Sharp & Dohme LLC $169,113.10 12/18/2023 Non-covered Recipient Entity
Senders Pediatrics
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 1042492803
Principal investigator 1 GlaxoSmithKline, LLC. $11,682.27 12/13/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1127784622
Principal investigator 1 PFIZER INC. $6,419.40 12/13/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046443369
Recipient PFIZER INC. $1,400.00 12/11/2023 Covered Recipient Physician BNT162 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046386547
Principal investigator 1 PFIZER INC. $2,072.72 12/08/2023 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046441311
Principal investigator 1 GlaxoSmithKline, LLC. $1,531.87 12/06/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1127789942
Principal investigator 1 PFIZER INC. $113.00 11/30/2023 Non-covered Recipient Entity
SENDERS PEDIATRICS
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 1046425671
Principal investigator 1 PFIZER INC. $2,533.56 11/25/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A PHASE 1 OPENLABEL AGEDESCENDING DOSEFINDING STUDY AND A PHASE 23 PLACEBOCONTROLLED RANDOMIZED DOUBLEBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE RSVPREF IN CHILDREN 2 TO 18 YEARS OF AGE AT HIGH RISK OF RSV DISEASE No dispute reported 06/30/2026 1045873007
Principal investigator 1 ModernaTX, Inc. $66.24 11/24/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1042219131
Principal investigator 1 ModernaTX, Inc. $130,086.62 11/22/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042219139
Principal investigator 1 PFIZER INC. $2,238.60 11/17/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046368775
Principal investigator 1 PFIZER INC. $14,901.12 11/15/2023 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046380109
Principal investigator 1 GlaxoSmithKline, LLC. $20,720.61 11/13/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1006243793
Principal investigator 1 GlaxoSmithKline, LLC. $9,423.49 11/10/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1127789940
Recipient PFIZER INC. $3,200.00 11/09/2023 Covered Recipient Physician PNEUMOCOCCAL VACCINE CONJ 7V CRM197 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046370749
Principal investigator 1 PFIZER INC. $5,583.24 11/08/2023 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046392679
Principal investigator 1 PFIZER INC. $2,292.48 11/07/2023 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046391193
Principal investigator 1 PFIZER INC. $1,913.50 10/31/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A PHASE 1 OPENLABEL AGEDESCENDING DOSEFINDING STUDY AND A PHASE 23 PLACEBOCONTROLLED RANDOMIZED DOUBLEBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE RSVPREF IN CHILDREN 2 TO 18 YEARS OF AGE AT HIGH RISK OF RSV DISEASE No dispute reported 06/30/2026 1045876989
Principal investigator 1 ModernaTX, Inc. $1,122.03 10/25/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042219129
Principal investigator 1 PFIZER INC. $2,463.50 10/25/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046427659
Principal investigator 1 PFIZER INC. $13,027.56 10/18/2023 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046393937
Principal investigator 1 PFIZER INC. $11,462.40 10/18/2023 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046422607
Principal investigator 1 PFIZER INC. $1,717.30 10/18/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046427175
Principal investigator 1 PFIZER INC. $12,327.90 10/14/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046393387
Recipient PFIZER INC. $3,200.00 10/13/2023 Covered Recipient Physician BNT162 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046348209
Principal investigator 1 PFIZER INC. $2,417.38 10/12/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A PHASE 1 OPENLABEL AGEDESCENDING DOSEFINDING STUDY AND A PHASE 23 PLACEBOCONTROLLED RANDOMIZED DOUBLEBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE RSVPREF IN CHILDREN 2 TO 18 YEARS OF AGE AT HIGH RISK OF RSV DISEASE No dispute reported 06/30/2026 1045873663
Recipient PFIZER INC. $940.00 10/12/2023 Covered Recipient Physician BNT162 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046385399
Principal investigator 1 PFIZER INC. $345.60 10/12/2023 Non-covered Recipient Entity
Senders PediatricsResearch
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046413055
Principal investigator 1 GlaxoSmithKline, LLC. $12,875.60 10/11/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1127784626
Principal investigator 1 PFIZER INC. $68,299.40 10/11/2023 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046427491
Principal investigator 1 GlaxoSmithKline, LLC. $14,455.98 10/09/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1006244053
Principal investigator 1 PFIZER INC. $13,550.00 10/07/2023 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046426397
Principal investigator 1 PFIZER INC. $40,378.04 10/05/2023 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046425731
Principal investigator 1 PFIZER INC. $1,717.30 10/04/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046424773
Principal investigator 1 ModernaTX, Inc. $49,309.38 09/27/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042219127
Principal investigator 1 PFIZER INC. $65,740.19 09/23/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A PHASE 1 OPENLABEL AGEDESCENDING DOSEFINDING STUDY AND A PHASE 23 PLACEBOCONTROLLED RANDOMIZED DOUBLEBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE RSVPREF IN CHILDREN 2 TO 18 YEARS OF AGE AT HIGH RISK OF RSV DISEASE No dispute reported 06/30/2026 1045879841
Principal investigator 1 PFIZER INC. $331.24 09/20/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046389727
Principal investigator 1 PFIZER INC. $1,077.44 09/15/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046403165
Principal investigator 1 GlaxoSmithKline, LLC. $17,172.84 09/06/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1006243823
Principal investigator 1 GlaxoSmithKline, LLC. $5,988.96 09/06/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1006244065
Principal investigator 1 PFIZER INC. $13,500.00 09/02/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A PHASE 1 OPENLABEL AGEDESCENDING DOSEFINDING STUDY AND A PHASE 23 PLACEBOCONTROLLED RANDOMIZED DOUBLEBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE RSVPREF IN CHILDREN 2 TO 18 YEARS OF AGE AT HIGH RISK OF RSV DISEASE No dispute reported 06/30/2026 1045879857
Principal investigator 1 ModernaTX, Inc. $69,002.71 08/25/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042219125
Principal investigator 1 PFIZER INC. $746.20 08/24/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046374689
Principal investigator 1 PFIZER INC. $2,379.78 08/23/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046418197
Principal investigator 1 GlaxoSmithKline, LLC. $40,577.17 08/16/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1127789944
Principal investigator 1 GlaxoSmithKline, LLC. $5,398.65 08/11/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1006243841
Principal investigator 1 PFIZER INC. $1,323.14 08/02/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046433533
Principal investigator 1 PFIZER INC. $1,611.61 07/26/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046472887
Principal investigator 1 PFIZER INC. $403.92 07/25/2023 Non-covered Recipient Entity
Senders PediatricsResearch
A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045878161
Principal investigator 1 PFIZER INC. $4,244.37 07/19/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046498739
Principal investigator 1 PFIZER INC. $13,443.95 07/18/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046411931
Principal investigator 1 GlaxoSmithKline, LLC. $14,792.86 07/12/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1006243817
Principal investigator 1 ModernaTX, Inc. $24,566.00 07/12/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042219123
Principal investigator 1 GlaxoSmithKline, LLC. $2,929.79 07/10/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1006221787
Principal investigator 1 PFIZER INC. $28,219.10 07/01/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046407755
Recipient Novavax Inc $2,224.00 06/28/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258533
Recipient Novavax Inc $4,920.00 06/20/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258749
Principal investigator 1 GlaxoSmithKline, LLC. $1,312.74 06/15/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDYTO No dispute reported 06/30/2026 1127784624
Principal investigator 1 PFIZER INC. $1,283.10 06/14/2023 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046530900
Recipient Novavax Inc $4,448.00 06/13/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258419
Principal investigator 1 ModernaTX, Inc. $54,464.66 06/09/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042219121
Principal investigator 1 GlaxoSmithKline, LLC. $8,197.02 06/08/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDYTO No dispute reported 06/30/2026 1127789936
Recipient Novavax Inc $4,974.00 06/08/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258417
Principal investigator 1 PFIZER INC. $3,392.00 06/05/2023 Non-covered Recipient Entity
Senders Pediatrics
A PHASE 1 OPENLABEL AGEDESCENDING DOSEFINDING STUDY AND A PHASE 23 PLACEBOCONTROLLED RANDOMIZED DOUBLEBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE RSVPREF IN CHILDREN 2 TO 18 YEARS OF AGE AT HIGH RISK OF RSV DISEASE No dispute reported 06/30/2026 1045865941
Principal investigator 1 PFIZER INC. $11,975.60 06/03/2023 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046529569
Recipient Novavax Inc $3,832.00 05/30/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258597
Principal investigator 1 PFIZER INC. $855.40 05/25/2023 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046531231
Recipient Novavax Inc $2,880.00 05/24/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258599
Principal investigator 1 PFIZER INC. $16,732.30 05/23/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046522459
Principal investigator 1 GlaxoSmithKline, LLC. $7,007.57 05/17/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE No dispute reported 06/30/2026 1006243799
Recipient Novavax Inc $960.00 05/16/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258669
Principal investigator 1 GlaxoSmithKline, LLC. $1,329.59 05/10/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1006243829
Recipient Novavax Inc $3,360.00 05/09/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258349
Recipient PFIZER INC. $940.00 05/08/2023 Covered Recipient Physician PNEUMOCOCCAL VACCINE CONJ 7V CRM197 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046430175
Principal investigator 1 GlaxoSmithKline, LLC. $12,091.95 05/04/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDYTO No dispute reported 06/30/2026 1127789938
Principal investigator 1 ModernaTX, Inc. $1,500.00 05/03/2023 Non-covered Recipient Entity
Senders Pediatrics
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041968298
Principal investigator 1 ModernaTX, Inc. $5,000.00 05/03/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042219117
Principal investigator 1 ModernaTX, Inc. $42,637.50 05/03/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042219119
Recipient Novavax Inc $160.00 05/03/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258345
Recipient PFIZER INC. $330.00 05/03/2023 Covered Recipient Physician BNT162 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046412185
Recipient Novavax Inc $7,520.00 04/26/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258667
Recipient Novavax Inc $2,240.00 04/18/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258479
Principal investigator 1 PFIZER INC. $3,731.00 04/12/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046475019
Principal investigator 1 GlaxoSmithKline, LLC. $1,343.55 04/06/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1006243805
Principal investigator 1 GlaxoSmithKline, LLC. $5,641.08 04/05/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1006243811
Principal investigator 1 PFIZER INC. $14,745.90 04/05/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046480370
Recipient Novavax Inc $160.00 04/04/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258711
Principal investigator 1 PFIZER INC. $13,754.88 04/04/2023 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046370081
Recipient Novavax Inc $8,480.00 03/29/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258477
Principal investigator 1 PFIZER INC. $3,209.70 03/29/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046450809
Principal investigator 1 ModernaTX, Inc. $34,217.27 03/24/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042219115
Recipient Novavax Inc $960.00 03/24/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258665
Principal investigator 1 PFIZER INC. $22,924.80 03/22/2023 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046459385
Principal investigator 1 PFIZER INC. $4,813.90 03/22/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046462633
Principal investigator 1 PFIZER INC. $38,833.21 03/21/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046476561
Recipient Novavax Inc $2,080.00 03/15/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258415
Principal investigator 1 PFIZER INC. $16,326.12 03/11/2023 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046455851
Principal investigator 1 GlaxoSmithKline, LLC. $6,874.72 03/08/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1006244059
Principal investigator 1 PFIZER INC. $7,809.28 03/08/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 1046435483
Principal investigator 1 PFIZER INC. $850.95 03/04/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 1046448969
Principal investigator 1 PFIZER INC. $18,746.00 03/03/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046460689
Principal investigator 1 ModernaTX, Inc. $29,171.78 03/01/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042219113
Recipient Novavax Inc $3,078.00 02/28/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258531
Principal investigator 1 PFIZER INC. $7,270.90 02/28/2023 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046375511
Principal investigator 1 PFIZER INC. $186,417.66 02/28/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046459827
Principal investigator 1 PFIZER INC. $318,320.33 02/24/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 1046462765
Recipient Novavax Inc $2,072.00 02/22/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258595
Recipient Novavax Inc $5,280.00 02/16/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258709
Principal investigator 1 GlaxoSmithKline, LLC. $388.83 02/10/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1006243849
Recipient Novavax Inc $800.00 02/09/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258593
Principal investigator 1 ModernaTX, Inc. $31,068.28 02/08/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042219111
Principal investigator 1 PFIZER INC. $855.40 02/07/2023 Non-covered Recipient Entity
Dr Shelly Senders
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046449537
Principal investigator 1 PFIZER INC. $3,266.05 02/03/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 1046448305
Recipient Novavax Inc $2,598.00 02/02/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258591
Principal investigator 1 ModernaTX, Inc. $46,392.56 02/01/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042219109
Principal investigator 1 PFIZER INC. $596.48 01/27/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 1046535227
Recipient Novavax Inc $6,034.00 01/25/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258475
Principal investigator 1 PFIZER INC. $1,192.96 01/25/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 1046535563
Principal investigator 1 PFIZER INC. $1,701.90 01/24/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 1046544193
Recipient Novavax Inc $6,750.00 01/20/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258529
Principal investigator 1 PFIZER INC. $3,438.72 01/18/2023 Non-covered Recipient Entity
Dr Shelly Senders
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046540741
Recipient PFIZER INC. $330.00 01/17/2023 Covered Recipient Physician PREVNAR 7 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046530589
Principal investigator 1 PFIZER INC. $9,566.70 01/12/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN No dispute reported 06/30/2026 1046534773
Principal investigator 1 PFIZER INC. $880.13 01/11/2023 Non-covered Recipient Entity
Dr Shelly David Senders MD INC
PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS No dispute reported 06/30/2026 1046535893
Recipient Novavax Inc $7,268.00 01/10/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258343
Principal investigator 1 GlaxoSmithKline, LLC. $1,166.51 01/06/2023 Non-covered Recipient Entity
DR SHELLY DAVID SENDERS MD INC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1006243835
Recipient Novavax Inc $9,158.00 01/06/2023 Covered Recipient Physician A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258527
Principal investigator 1 AstraZeneca UK Limited $3,637.10 01/05/2023 Non-covered Recipient Entity
SENDERS PEDIATRICS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) No dispute reported 06/30/2026 991129123